Angioedema: Etiology, pathophysiology, current and emerging therapies

Journal of Emergency Medicine

Volumn 45, Issue 5, 2013, Pages 789-796

  Lewis, Lawrence M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angioedema; angiotensin converting enzyme inhibitor induced angioedema; ecallantide; icatibant; kallikrein kinin system

Indexed keywords

ADRENALIN; AMINOCAPROIC ACID; ANTIHISTAMINIC AGENT; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; ENALAPRIL; ICATIBANT; OMAPATRILAT; STANOZOLOL; TRANEXAMIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANGIOTENSIN CONVERTING ENZYME INHIBITOR INDUCED ANGIOEDEMA; DIARRHEA; DRUG INDUCED DISEASE; EMERGENCY WARD; FACE; FEVER; GENITAL SYSTEM; HEADACHE; HEREDITY; HUMAN; IDIOPATHIC ANGIOEDEMA; INCIDENCE; INJECTION SITE REACTION; KALLIKREIN KININ SYSTEM; LIMB; LIP; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM BLOCKER ANGIOEDEMA; RESPIRATION CONTROL; REVIEW; RISK FACTOR; SIDE EFFECT; THROAT; TONGUE; UNITED STATES; VISCERA;

ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITOR-INDUCED ANGIOEDEMA; ECALLANTIDE; ICATIBANT; KALLIKREIN-KININ SYSTEM;

ADRENERGIC BETA-ANTAGONISTS; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; ENDOSCOPY; HUMANS; INCIDENCE; INTUBATION, INTRATRACHEAL; KALLIKREINS; PEPTIDES; RISK FACTORS;

EID: 84886952305     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2013.03.045     Document Type: Article

References (66)

1. W. Vleeming, J.G.C. van Amsterdam, BHCh Stricker, and D.J. de Wildt ACE inhibitor-induced angioedema. Incidence, prevention and management Drug Saf 18 1998 171 188
2. K. Bork Recurrent angioedema and the threat of asphyxiation Dtsch Arztebl Int 107 2010 408 414
3. Palmer M, Rosenbaum S. Clinical practice guideline: initial evaluation and management of patients presenting with acute urticaria or angioedema. American Academy of Emergency Medicine. Available at: http://www.aaem.org/ education/urticaria-angioedema.php. Published July 10, 2006. Accessed August 1, 2011.
4. A. Banerji Current treatment of hereditary angioedema: an update on clinical studies Allergy Asthma Proc 31 2010 398 406
5. E. Frigas, and M. Park Idiopathic recurrent angioedema Immunol Allergy Clin North Am 26 2006 739 751
6. A. Banerji, S. Clark, M. Blanda, F. LoVecchio, B. Snyder, and C.A. Camargo Jr. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department Ann Allergy Asthma Immunol 100 2008 327 332
7. H.M. Bluestein, T.A. Hoover, A.S. Banerji, C.A. Camargo Jr., A. Reshef, and P. Herscu Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department Ann Allergy Asthma Immunol 103 2009 502 507
8. C.A. Megerian, J.E. Arnold, and M. Berger Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment Laryngoscope 102 1992 256 260
9. E.C. Pigman, and J.L. Scott Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors Am J Emerg Med 11 1993 350 354
10. G.M. Gabb, P. Ryan, L.M. Wing, and K.A. Hutchinson Epidemiological study of angioedema and ACE inhibitors Aust NZJ Med 26 1996 777 782
11. V.M. Temino, and R.S. Stokes Peebles Jr. The spectrum and treatment of angioedema Am J Med 121 2008 282 286
12. M. Bas, V. Adams, T. Suvorava, T. Niehues, T.K. Hoffmann, and G. Kojda Nonallergic angioedema: role of bradykinin Allergy 62 2007 842 856
13. J.B. Kostis, H.J. Kim, and J. Rusnak Incidence and characteristics of angioedema associated with enalapril Arch Intern Med 165 2005 1637 1642
14. M.A. Riedl, and A.M. Casillas Adverse drug reactions: types and treatment options Am Fam Physician 68 2003 1781 1791
15. P. Gylffors, G. Bochenek, and J. Overholt Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib J Allergy Clin Immunol 111 2003 1116 1121
16. R.H. Champion, S.O. Roberts, R.G. Carpenter, and J.H. Roger Urticaria and angio-edema. A review of 554 patients Br J Dermatol 81 1969 588 597
17. M. Lunn, and E. Banta Ecallantide for the treatment of hereditary angiodema in adults Clin Med Insights Cardiol 5 2011 49 54
18. B.L. Zuraw, and J. Herschbach Detection of C1 inhibitor mutations in patients with hereditary angioedema J Allergy Clin Immunol 105 2000 541 546
19. K. Bork, S. Bornstedt, P. Koch, and H. Traupe Hereditary angioedema with normal C1-inhibitor activity in women Lancet 356 2000 213 217
20. K.E. Binkley, and A. Davis III Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema J Allergy Clin Immunol 106 2000 546 550
21. A.P. Kaplan Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy J Allergy Clin Immunol 126 2010 918 925
22. D.R. Miller, S.A. Oliveria, D.R. Berlowitz, B.G. Fincke, P. Stang, and D.E. Lillienfeld Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors Hypertension 51 2008 1624 1630
23. Z.H. Israili, and W.D. Hall Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology Ann Intern Med 117 1992 234 242
24. E.E. Slater, D.D. Merrill, and H.A. Guess Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition JAMA 260 1988 967 970
25. N.J. Brown, W.A. Ray, M. Snowden, and M.R. Griffin Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema Clin Pharmacol Ther 60 1996 8 13
26. A.P. Kaplan Kinins, airway obstruction, and anaphylaxis Chem Immunol Allergy 95 2010 67 84
27. T. Hoover, M. Lippmann, E. Grouzmann, F. Marceau, and P. Herscu Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors Clin Exp Allergy 40 2010 50 61
28. R.M. Fryer, J. Segreti, and P.N. Banfor Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema Br J Pharmacol 153 2008 947 955
29. N.L.M. Cruden, and D.E. Newby Therapeutic potential of icatibant (HOE-140, JE-049) Expert Opin Pharmacother 9 2008 2383 2390
30. C. Shima, M. Majima, and M. Katori A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma Jpn J Pharmacol 60 1992 111 119
31. A. Agostoni, E. Aygören-Pürsün, and K.E. Binkley Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond J Allergy Clin Immunol 114 2004 S51 S131
32. 9-bradykinin J Pharmacol Exp Ther 303 2002 232 237
33. M. Cugno, J. Nussberger, M. Cicardi, and A. Agostoni Bradykinin and the pathophysiology of angioedema Int Immunopharmacol 3 2003 311 317
34. A.P. Kaplan, and B. Ghebrehiwet The plasma bradykinin-forming pathways and its interrelationships with complement Mol Immunol 47 2010 2161 2169
35. CINRYZE [package insert] January 2012 ViroPharma Biologics Exton, PA
36. Winters M, Rosenbaum S. Clinical practice statement: what is the emergency department management of patients with angioedema secondary to an ACE-inhibitor? American Academy of Emergency Medicine. Available at: http://www.aaem.org/emtopics/angioedema.pdf. Published April 11, 2011. Accessed August 1, 2011.
37. M. Nasir, and G. Sharma Angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker-induced angioedema: overuse of ineffective treatment 2011 American Academy of Allergy Asthma and Immunology Annual Meeting San Francisco, CA Abstract 394
38. P. Geppetti Sensory neuropeptide release by bradykinin: mechanisms and pathophysiological implications Regul Pept 47 1993 1 23
39. C.M.S. Fewtrell, J.C. Foreman, and C.C. Jordan The effects of substance P on histamine and 5-hydroxytryptamine release in the rat J Physiol 330 1982 393 411
40. BERINERT [package insert] December 2011 CSL Behring Kanakee, IL
41. FDA News Release. FDA approves berinert to treat abdominal attacks, facial swelling associated with hereditary angioedema. October 9, 2009. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm186257.htm. Accessed March 1, 2012.
42. B.L. Zuraw, P.J. Busse, and M. White Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema N Engl J Med 363 2010 513 522
43. B.P. Morgan Editorial. Hereditary angioedema: therapies old and new N Engl J Med 363 2010 581 583
44. L. Varga, and H. Farkas rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency Expert Rev Clin Immunol 7 2011 143 153
45. B. Gelée, P. Michel, R. Haas, and F. Boishardy [Angiotensin-converting enzyme inhibitor-related angioedema: treatment in an emergency room with complement C1 inhibitor concentrate.] In French Rev Med Interne 29 2008 516 519
46. E.W. Nielsen, and S. Gramstad Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate Acta Anaesthesiol Scand 50 2006 120 122
47. O. Steinbach, R. Schweder, and B. Freitag [C1-esterase inhibitor in ACE inhibitor-induced severe angioedema of the tongue] In German Anaesthesiol Reanim 26 2001 133 137
48. M. Pekdemir, M. Ersel, and E. Aksay Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department J Emerg Med 33 2007 137 139
49. M. Prematta, J.G. Gibbs, and E.L. Pratt Fresh frozen plasma for the treatment of hereditary angioedema Ann Allergy Asthma Immunol 98 2007 383 388
50. M. Karim, and A. Masood Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema J Allergy Clin Immunol 109 2002 370 371
51. M.R. Warrior, C.A. Copilevitz, M.S. Dykewicz, and R.G. Slavin Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema Ann Allergy Asthma Immunol 92 2004 573 575
52. M.M. Frank, and H. Jiang New therapies for hereditary angioedema: disease outlook changes dramatically J Allergy Clin Immunol 121 2008 272 280
53. KALBITOR [package insert] December 2009 Dyax Cambridge, MA
54. N. Richards, J. Cohn, and C. McDaniels Angiotensin converting enzyme inhibitor induced angioedema treated with ecallantide: a case report Ann Allergy Asthma Immunol 107 Suppl. 1 2011 A72
55. J.R. Cohn, C. McDaniels, and N. Richards Prompt reversal of airway obstruction secondary to angiotensin converting enzyme inhibitor (ACEI) induced angioedema by ecallantide: a case report J Allergy Clin Immunol 129 Suppl. 1 2012 AB828
56. C. McDaniel, M. Baram, and C. Wordell Ecallantide treatment for angiotensin converting enzyme inhibitor induced angioedema (ACEI-IA): a case series and pharmacoeconomic assessment Crit Care Med 39 Suppl. 2011 260
57. National Institutes of Health. NCT01343823: evaluation of ecallantide for treatment of angiotensin converting enzyme (ACE) inhibitor induced angioedema. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01343823. Published April 27, 2011. Updated September 30, 2011. Accessed October 23, 2011.
58. National Institutes of Health. NCT01036659: Evaluation of ecallantide for the acute treatment of angiotensin converting enzyme inhibitor induced angioedema (ACE). Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01036659. Published December 18, 2009. Updated August 17, 2010. Accessed October 23, 2011.
59. FIRAZYR [package insert] August 2011 Shire Orphan Therapies Lexington, MA
60. M. Cicardi, A. Banerji, and F. Bracho Icatibant, a novel bradykinin B2 receptor antagonist, is effective in the treatment of acute attacks in patients with hereditary angioedema N Engl J Med 363 2010 532 541
61. 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial Ann Allergy Asthma Immunol 107 2011 529 537
62. Drugs.com. Jerini Receives European Commission Approval for Firazyr (Icatibant) in the Treatment of HAE. July 15, 2008. Available at: http://www.drugs.com/news/jerini-receives-european-commission-approval-firazyr- icatibant-hae-8404.html. Accessed March 1, 2012.
63. D.V. Perez, S. Infante, G. Marco, and J.M. Zubeldia Angioedema induced by angiotensin-converting enzyme inhibitors: two cases of successful treatment with a novel B2 bradykinin antagonist 2011 American Academy of Allergy Asthma and Immunology Annual Meeting San Francisco, CA Abstract 393
64. M. Bas, J. Greve, and K. Stelter Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series Ann Emerg Med 56 2010 278 282
65. P.W. Schmidt, M.M. Hirschl, and F. Trautinger Case letter. Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant J Am Acad Dermatol 63 2010 913 914
66. National Institutes of Health. NCT01154361: Amelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01154361. Published June 29, 2010. Updated March 4, 2011. Accessed October 23, 2011.